Pasithea Therapeutics Corp. 宣布，其候选药物Pas-4在临床研究中表现出良好的安全性特征。数据显示，所有观察到的药物相关不良事件均为1级或2级，未出现更高级别（3级及以上）的安全性事件。
这一积极的安全数据为Pas-4的后续临床开发奠定了重要基础。通常，药物在早期临床试验中展现出可控的安全性，是推进至更后期研究阶段的关键前提。投资者和分析师普遍关注生物技术公司候选药物的安全性，因为这直接影响其监管审批前景和商业化潜力。
公司表示，将继续推进Pas-4的相关研究计划，并评估其在目标适应症中的治疗潜力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.